FDA AdCom to mull full approval for Biogen/Eisai’s Leqembi in Alzheimer’s disease
After Leqembi gained accelerated approval in Alzheimer’s disease in January, a high-stakes AdCom will debate whether the antibody warrants a full approval this June.
3M WP
Innovent Biologics begins subject dosing in plaque psoriasis therapy trial
What is BioGPT and what does it mean for healthcare?
mRNA vaccines: Four major clinical trial readouts to watch in 2023
First Wave BioPharma to initiate trial of adrulipase for cystic fibrosis
Pipeline Moves: Trial completion bumps advancement prospects for AstraZeneca’s oncology drug
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
BMJ finds 96% of oncology drug developers inadequately include minority groups
